8-K: LifeMD Reports Q3 Results, Secures $12.5M Loan

LifeMD announced third quarter 2026 results, reporting $44.6 million in revenue and a $0.4 million adjusted EBITDA loss, while also securing a $12.5 million loan and entering strategic partnerships.

Summary

• LifeMD reported third quarter 2026 revenue of $44.6 million, a 7% decrease year-over-year, and an adjusted EBITDA loss of $0.4 million, which was within guidance but a sequential improvement.
• The company's GAAP net loss from continuing operations was $5.2 million, or $0.11 per share, an improvement from the prior quarter's loss of $8.4 million.
• Total active subscribers grew 13% year-over-year to approximately 350,000.
• LifeMD secured a $12.5 million senior secured term loan to replace its previous credit facility and entered into agreements to dispense GLP-1 medications and an exclusive relationship with AT&T.
• The company lowered its full-year 2026 revenue guidance to $188-$191 million (from $205.5-$212.5 million) and adjusted EBITDA guidance to a loss of $12.6-$10.6 million (from a loss of $6.0 million to breakeven).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to a significant revenue miss, lowered full-year guidance, and a widening adjusted EBITDA loss for Q4, despite some sequential improvements and strategic partnerships.

Positives

• Sequential improvement in adjusted EBITDA, moving from a loss of $3.5 million in Q2 2026 to a loss of $0.4 million in Q3 2026.
• Significant reduction in selling and marketing expenses by 34% sequentially ($9.5 million reduction).
• Total active subscribers increased 13% year-over-year to approximately 350,000.
• LifeMD Pharmacy shipment volume grew 58.3% year-over-year.
• Secured a $12.5 million senior secured term loan, providing greater flexibility and replacing the previous credit facility.
• Entered into arrangements with Novo Nordisk and Eli Lilly to dispense self-pay branded GLP-1 medications.
• Established an exclusive relationship with AT&T to offer services to its 100 million customers and 110,000 employees.
• Gross margin remained strong at approximately 82%.

Negatives

• Third quarter revenue of $44.6 million was below the prior-year period ($47.7 million) and below company expectations.
• Full-year 2026 revenue guidance was significantly reduced to $188-$191 million from $205.5-$212.5 million.
• Full-year 2026 adjusted EBITDA guidance was revised to a loss of $12.6-$10.6 million, a substantial increase from the previous guidance of a loss of $6.0 million to breakeven.
• Fourth quarter 2026 adjusted EBITDA guidance is a loss of $4 million to $2 million, indicating a worsening trend from Q3.
• Gross margin decreased to 82% from 85% in the prior-year period, primarily due to a change in revenue recognition for branded fulfillment arrangements.
• GAAP net loss from continuing operations was $5.2 million for the quarter.

Risks

• The company's ability to achieve its revised revenue and profitability targets given the significant guidance reduction.
• Potential challenges in ramping up new partnerships and enterprise healthcare offerings.
• The impact of increased marketing spend or patient acquisition costs on future profitability.
• The company's reliance on future revenue growth to manage its debt obligations and operating expenses.
• The competitive landscape for virtual primary care and pharmacy services.
• The potential for regulatory changes affecting telehealth and pharmaceutical services.

Future Outlook

The company expects fourth quarter 2026 revenue between $46 million and $49 million, and an adjusted EBITDA loss between $4 million and $2 million. For the full year 2026, revenue is projected to be between $188 million and $191 million, with adjusted EBITDA loss between $12.6 million and $10.6 million.

Management Comments

• "We ended the quarter with approximately 350,000 active subscribers, up 13% from a year ago and nearly flat from the second quarter, despite spending $9.5 million less on marketing."
• "Were helping more people access high-quality healthcare, and were getting more efficient at doing it."
• "Revenue of $44.6 million was below our guidance, and we are resetting our outlook for the fourth quarter and full year."
• "Our focus now is turning this work into revenue growth while maintaining the operating discipline we established this quarter."
• "The decline primarily reflects a change in presentation, not economics: under our new branded fulfillment arrangements, medications fulfilled by our own pharmacy are recognized on a gross revenue basis."

Industry Context

StockSavvy.ai notes that LifeMD's results and revised guidance reflect broader industry pressures in telehealth and pharmacy services, including increased competition, evolving regulatory landscapes, and the need for efficient patient acquisition. The strategic partnerships with pharmaceutical companies for GLP-1 medications and with AT&T highlight a trend towards specialized offerings and broader distribution channels within the virtual care sector.

Legal Proceedings

• The company is involved in litigation, including a class action complaint captioned Johnston v. LifeMD, Inc., et al., alleging violations of securities laws.
• Costs related to a class action complaint in Marden v. LifeMD, Inc. were also included for the prior year.

Stakeholder Impact

• Shareholders: Negative impact due to reduced revenue guidance, increased expected losses, and potential dilution from warrant exercise.
• Creditors: The new $12.5 million loan provides financial flexibility, but covenants related to net revenue and debt approval will need to be monitored.
• Employees: Potential impact on morale due to financial performance and revised outlook, though new partnerships may create growth opportunities.
• Customers: Continued access to virtual primary care and pharmacy services, with new offerings like GLP-1 medications and AT&T benefits.

Next Steps

• Begin marketing the enterprise healthcare offering to businesses across the country in the fourth quarter.
• Continue to focus on turning strategic initiatives into revenue growth while maintaining operating discipline.
• Monitor and manage the impact of new branded fulfillment arrangements on revenue recognition and gross margin.
• Utilize the new $12.5 million loan to fund working capital requirements for branded fulfillment arrangements.

Key Dates

Recommendation

The company has secured new financing and entered into strategic partnerships, which are positive developments. However, the significant reduction in revenue guidance and widening of adjusted EBITDA loss for the full year indicate substantial headwinds. While sequential improvements in EBITDA and subscriber growth are encouraging, the overall financial performance and outlook suggest a cautious approach. A 'hold' recommendation reflects the balance between potential upside from new initiatives and the significant risks associated with achieving revised financial targets.

Keywords

virtual primary care, pharmacy services, telehealth, GLP-1 medications, subscriber growth, revenue guidance, adjusted EBITDA, loan agreement